Wu Jing, Neale Natalie, Huang Yuqian, Bai Harrison X, Li Xuejun, Zhang Zishu, Karakousis Giorgos, Huang Raymond, Zhang Paul J, Tang Lei, Xiao Bo, Yang Li
Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
World Neurosurg. 2018 Apr;112:e812-e822. doi: 10.1016/j.wneu.2018.01.163. Epub 2018 Jan 31.
It is becoming increasingly common to incorporate chemotherapy (CT) with radiotherapy (RT) in the treatment of low-grade gliomas (LGGs) after surgical resection. However, there is a lack of literature comparing survival of patients who underwent RT or CT alone.
The U.S. National Cancer Data Base was used to identify patients with histologically confirmed, World Health Organization grade 2 gliomas who received either RT alone or CT alone after surgery from 2004 to 2013. Overall survival (OS) was evaluated by Kaplan-Meier analysis, multivariable Cox proportional hazard regression, and propensity-score-matched analysis.
In total, 2253 patients with World Health Organization grade 2 gliomas were included, of whom 1466 (65.1%) received RT alone and 787 (34.9%) CT alone. The median OS was 98.9 months for the RT alone group and 125.8 months for the CT alone group. On multivariable analysis, CT alone was associated with a significant OS benefit compared with RT alone (hazard ratio [HR], 0.405; 95% confidence interval, 0.277-0.592; P < 0.001). On subgroup analyses, the survival advantage of CT alone over RT alone persisted across all age groups, and for the subtotal resection and biopsy groups, but not in the gross total resection group. In propensity-score-matched analysis, CT alone still showed significantly improved OS compared with RT alone (HR, 0.612; 95% confidence interval, 0.506-0.741; P < 0.001).
Our results suggest that CT alone was independently associated with longer OS compared with RT alone in patients with LGGs who underwent surgery.
在手术切除后,低级别胶质瘤(LGG)的治疗中采用化疗(CT)联合放疗(RT)的情况越来越普遍。然而,缺乏比较单纯接受放疗或化疗患者生存率的文献。
利用美国国家癌症数据库,识别2004年至2013年间组织学确诊为世界卫生组织2级胶质瘤且术后仅接受放疗或化疗的患者。通过Kaplan-Meier分析、多变量Cox比例风险回归和倾向评分匹配分析评估总生存期(OS)。
总共纳入了2253例世界卫生组织2级胶质瘤患者,其中1466例(65.1%)仅接受放疗,787例(34.9%)仅接受化疗。单纯放疗组的中位总生存期为98.9个月,单纯化疗组为125.8个月。多变量分析显示,与单纯放疗相比,单纯化疗具有显著的总生存期获益(风险比[HR],0.405;95%置信区间,0.277 - 0.592;P < 0.001)。亚组分析表明,单纯化疗相对于单纯放疗的生存优势在所有年龄组以及次全切除和活检组中均持续存在,但在全切组中不存在。倾向评分匹配分析显示,与单纯放疗相比,单纯化疗仍显示总生存期显著改善(HR,0.612;95%置信区间,0.506 - 0.741;P < 0.001)。
我们的结果表明,在接受手术的低级别胶质瘤患者中,与单纯放疗相比,单纯化疗独立地与更长的总生存期相关。